Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

Thomas Chateau; Stefanos Bonovas; Catherine Le Berre; Nicolas Mathieu; Silvio Danese; Laurent Peyrin-Biroulet

doi:10.1093/ecco-jcc/jjz095

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

Thomas Chateau, Stefanos Bonovas, Catherine Le Berre, Nicolas Mathieu, Silvio Danese, Laurent Peyrin-Biroulet

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND AND AIMS: We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].

METHODS: We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.

RESULTS: Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.

CONCLUSIONS: There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.

Original language	English
Pages (from-to)	1569-1577
Number of pages	9
Journal	Journal of Crohn's & colitis
Volume	13
Issue number	12
DOIs	https://doi.org/10.1093/ecco-jcc/jjz095
Publication status	Published - Dec 10 2019

Access to Document

10.1093/ecco-jcc/jjz095

Cite this

@article{7c8ef9de437049c88c53acfb67afa0d3,

title = "Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review",

abstract = "BACKGROUND AND AIMS: We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].METHODS: We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.RESULTS: Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.CONCLUSIONS: There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.",

author = "Thomas Chateau and Stefanos Bonovas and {Le Berre}, Catherine and Nicolas Mathieu and Silvio Danese and Laurent Peyrin-Biroulet",

note = "Copyright {\textcopyright} 2019 European Crohn{\textquoteright}s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.",

year = "2019",

month = dec,

day = "10",

doi = "10.1093/ecco-jcc/jjz095",

language = "English",

volume = "13",

pages = "1569--1577",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease

T2 - A Systematic Review

AU - Chateau, Thomas

AU - Bonovas, Stefanos

AU - Le Berre, Catherine

AU - Mathieu, Nicolas

AU - Danese, Silvio

AU - Peyrin-Biroulet, Laurent

PY - 2019/12/10

Y1 - 2019/12/10

N2 - BACKGROUND AND AIMS: We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].METHODS: We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.RESULTS: Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.CONCLUSIONS: There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.

AB - BACKGROUND AND AIMS: We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].METHODS: We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.RESULTS: Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.CONCLUSIONS: There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.

U2 - 10.1093/ecco-jcc/jjz095

DO - 10.1093/ecco-jcc/jjz095

M3 - Article

C2 - 31076751

SN - 1873-9946

VL - 13

SP - 1569

EP - 1577

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - 12

ER -

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

Abstract

Access to Document

Fingerprint

Cite this